Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations


Company continues to pursue strategic partnership to further...
-Today at 07:02 am- MarketScreener

Related Keywords

Israel ,Israeli ,Usama Gergis ,Terry Coelho ,Steven Devine ,Abbey Jenkins ,Michele Korfin ,Morgan Stanley ,Transactions Committee ,Drug Administration ,Twitter ,Sidney Kimmel Cancer Center ,Israeli Innovation Authority ,Community Fund ,Moelis Company ,Insightec Ltd ,International Society For Cell ,Nasdaq ,National Marrow Donor Program ,Gamida Cell Inc ,Gamida Cell Ltd ,Medicaid Services ,Department Of Veterans Affairs ,Department Of Defense ,Veterans Affairs ,Exchange Commission ,Centers For Medicare ,Thomas Jefferson University ,Emissions Solutions Inc ,Gamida Cell ,Chief Executive Officer ,Chief Operating ,Chief Commercial Officer ,Quarter Highlights ,Gamida Cell Assist ,Cellular Therapy ,Chief Financial Officer ,Chief Financial ,Jeremy Blank ,Chief Investment Officer ,York Capital Management ,Vice President ,Advanced Emissions Solutions ,Investor Day ,Chief Medical Officer ,International Society ,Gene Therapy ,Science Translational Medicine ,Omisirge Phase ,All Rights ,Private Securities Litigation Reform Act ,Risk Factors ,Quarterly Report ,Fair Value ,Markets ,